New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. Schwartzberg скачать в хорошем качестве

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. Schwartzberg

Although there has been considerable progress in the treatment of early stage HER2+ breast cancer, there are still areas of unmet need. Specifically, there are patients that still go on to develop metastatic disease despite optimal neoadjuvant and adjuvant therapy. Moreover, a good percentage of these patients are relapsing in the CNS, despite the gains we have achieved with T-DM1 in the post neoadjuvant setting. In the metastatic setting, first line therapy with a taxane, trastuzumab and pertuzumab has become standard. However, with the approval of several other agents optimizing sequencing strategies remains an area of active investigation. Balancing side effects, dosing schedules as well as efficacy of these agents continues to be challenging. Patient goals of care are also being given a much more significant place in therapeutic decision making. Reshma Mahtani, DO, from Sylvester Comprehensive Cancer Center, and Lee Schwartzberg, MD, FACP, from West Cancer Center & Research Institute, discuss the newest information on data and supporting data leading to better selection of treatment for early stage and metastatic HER2+ breast cancer. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Amedco LLC designates this activity for a maximum of 1 ANCC contact hours. Pharmacists and Pharmacy Technicians Amedco LLC designates this activity for a maximum of 1 knowledge-based CPE contact hours. How to Get Your Certificate 1. Go to https://workshop-evaluator.herokuapp.... 2. Evaluate the meeting. 3. Print all pages of your certificate for your records. Questions? Email Certificate@AmedcoEmail.com Learner's Notification: https://bit.ly/3AAqiOG